Second Sight Medical Products, Inc. (EYES)
Chart Events
Performance Outlook
| Previous Close | 1.7600 |
| Open | 1.7500 |
| Bid | 1.7000 x 1100 |
| Ask | 1.7100 x 1300 |
| Day's Range | 1.6600 - 1.7700 |
| 52 Week Range | 0.6910 - 6.4000 |
| Volume | 972,740 |
| Avg. Volume | 2,384,919 |
| Market Cap | 39.695M |
| Beta (5Y Monthly) | 2.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1480 |
| Earnings Date | Jun 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GKOS: Raising target price to $66.00
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Business Wire
Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System ("Orion") at UCLA Medical Center ("UCLA"). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine ("Baylor"), was paused for in-person visits following the guidelines for clinical trials at each institution in March 2020 due to COVID-19. Study visits have now been resumed; several UCLA participants are being examined this week, and Baylor is anticipated to resume its study soon.
- ACCESSWIRE
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of the Following Companies: Second Sight Medical Products, Inc. (NasdaqGS - EYES), A10 Networks, Inc. (NYSE - ATEN), MoSys, Inc. (NasdaqGS - MOSY)
BALA CYNWYD, PA / ACCESSWIRE / June 23, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims regarding the following companies for possible breaches of fiduciary ...
- Zacks
Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
